Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04634825 |
|---|---|
| Brief Title: | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer |
| First Submitted : | November 12, 2020 |
| First Submitted that Met QC Criteria : | November 12, 2020 |
| First Posted : | November 18, 2020 |
| Last Update Submitted that Met QC Criteria : | November 2, 2022 |
| Last Update Posted : | November 7, 2022 |